Antibe Therapeutics today announced that its subsidiary Citagenix has launched PentOS OI Max for the dental biologics market. PentOS OI Max is the newest member of the PentOS OI family of bone grafts for oral and maxillofacial surgery.
PentOS OI Max is an inductive collagen matrix that can be mixed with the clinician’s choice of patient-derived concentrates (including stem cells and blood components). Osteoinductivity is demonstrated in each lot in both in vivo and in vitro assays using independent laboratories. In vitro testing demonstrated levels of bone morphogenetic protein (“BMP”) up to 40-times that of the control. BMP is a naturally occurring growth factor found in the human body and plays a crucial role in bone formation. In vivo testing demonstrates all five elements of bone formation are present in our PentOS OI™ grafts: chondrocytes, osteocytes, bone marrow cells, cartilage, and new bone. In vitro studies also demonstrated excellent cell viability and proliferation.
“Citagenix continues to augment its portfolio with the addition of high-quality products that support optimal patient outcomes at a competitive price point,” said Dan Legault, Antibe’s CEO. “Being the ‘portfolio-of-choice’ for dentists and oromaxillofacial surgeons is important to our global growth strategy and is supported by an active business development funnel.”
PentOS OI Max will be offered in the Canadian market through our direct sales force and globally via our network of distribution partners.
Antibe’s subsidiary Citagenix sells and markets tissue regenerative products servicing the orthopedic and dental marketplaces.
Antibe Therapeutics